Table 2.
Evaluation of safety with equipment of VLf or placebo frames.
| No. of Subjects | 41 Patients | VLf (n = 20) | Control (n = 21) |
|---|---|---|---|
| Associated adverse reactions | No. of subjects | 0 | 0 |
| Conjunctival hyperemia | 0 | 0 | |
| Corneal abnormality | 0 | 0 | |
| Lens opacity | 0 | 0 | |
| Inflammation of anterior chamber | 0 | 0 | |
| Fundus abnormality | 0 | 0 | |
| Abnormal findings in OCT | 0 | 0 | |
| Periorbital skin abnormality | 0 | 0 | |
| Adverse events | No. of subjects | 11 | 7 |
| Influenza infection | 1 | 1 | |
| EB virus infection | 1 | 0 | |
| Streptococcal infection | 1 | 0 | |
| Epipharyngitis | 3 | 2 | |
| Mumps | 1 | 0 | |
| Sudden deafness | 1 | 0 | |
| Nausea | 0 | 1 | |
| Abdominal pain | 0 | 1 | |
| Application site erythema | 1 | 1 | |
| Fracture | 1 | 2 | |
| Eyelid contusion | 1 | 0 |
VLf: violet light eyeglasses frames; OCT: optical coherence tomography.